This profile outlines the comprehensive transformation of an Indian listed entity currently pivoting from a legacy IT and tele-medicine focus toward a diversified industrial model encompassing **Textiles**, **Medical Packaging**, and **Surgical Instruments**. Following a change in control in **May 2025**, the company is undergoing a fundamental strategic reorientation under its new parentage. --- ### **Corporate Transformation & Strategic Pivot** The company is currently executing a Board-approved transition to align its operations with the industrial expertise of its new majority shareholder. * **Corporate Rebranding:** To reflect its new industrial identity, the company is changing its name from **Kashyap Tele-Medicines Limited** to **June Industries Limited**. * **Strategic Diversification:** The **Memorandum of Association (MoA)** is being amended to shift the primary business focus to the **Textile Business** and the **Packaging of Medical Instruments**. * **Operational Relocation:** The registered office is shifting from **Mumbai** to **Mahape, Navi Mumbai**, to centralize operations and improve efficiency. * **Asset Continuity:** New management has committed to a **two-year moratorium** on disposing of significant company assets, ensuring stability during the transition period. --- ### **Ownership Structure & The 2025 Open Offer** A significant change in management and control occurred in **May 2025**, making the company a subsidiary of **June Enterprises Private Limited**. | Event | Details | | :--- | :--- | | **Acquirer / Holding Company** | **June Enterprises Private Limited** | | **Transaction Date (SPA)** | **March 05, 2025** | | **Acquisition Price** | **₹1.50** per equity share | | **Shares Acquired via SPA** | **1,68,72,900** shares (**35.35%** stake) | | **Open Offer Size** | Up to **1,24,07,720** shares (**26.00%** stake) | | **Current Promoter Holding** | **2,90,54,018** shares (**60.88%**) as of **August 2025** | --- ### **Expanded Industrial & Medical Portfolio** Leveraging the parent company’s expertise, the company is expanding into the manufacturing, trading, and distribution of a comprehensive range of medical consumables and hardware: * **Medical Packaging:** Sterilization monitoring products and specialized packaging for diagnostic equipment. * **Surgical Instruments & Disposables:** * Syringes (disposable/non-disposable), needles, and blood administration sets. * Catheters (Foley's, Nelaton, Suction) and **I.V. cannulas**. * **Medical Hardware:** Stethoscopes, sphygmomanometers, microscopes, and medical kits. * **Textiles:** A new core segment focused on industrial textile manufacturing and distribution. --- ### **Legacy IT Operations & Digital Integration** While pivoting to industrial sectors, the company maintains a secondary focus on **Information Technology Related Services** and **Software Sales**. * **Current IT Scope:** Software development, maintenance, internet services, e-commerce solutions, and website design. * **Digital Transformation Strategy:** The company intends to integrate **AI, Generative AI, Machine Learning, Cloud Computing, and IoT** into its new industrial workflows to provide data-driven, hyper-personalized solutions. * **Target Verticals:** Continued engagement in **BFSI, Retail, Healthcare, and Manufacturing** through "outcome-based delivery" models. --- ### **Financial Performance & Capital Structure** The company maintains a lean financial profile with **zero fixed assets** and is working toward stabilizing its bottom line. **Key Financial Metrics (FY23–FY25):** | Metric (in ₹ Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **19.20** | **19.20** | **19.65** | | **EBITDA** | **(0.03)** | **(2.96)** | **0.42** | | **Profit After Tax (PAT)** | **(0.03)** | **(3.00)** | **0.31** | | **Shareholder Funds** | **63.95** | **63.98** | **66.98** | | **Return on Net Worth (RONW)** | **(4.69%)** | **(4.69%)** | **0.46%** | **Revenue Breakdown (FY25):** * **Software Sales:** **₹15.60 Lakhs** (Primary revenue driver). * **Projects and Services:** **₹3.60 Lakhs**. **Capitalization:** * **Authorized Share Capital:** **₹15,00,00,000** (15 Cr shares at **₹1/-**). * **Paid-up Capital:** **₹4,77,22,000**. --- ### **Risk Profile & Mitigation Strategies** Investors should note the following risks associated with the company’s current transition and historical performance: * **Liquidity & Credit Risk:** The company has faced consecutive years of cash losses (**₹0.03 Lakhs** in FY25). Cash and bank balances stood at **₹0.05 Lakhs** in March 2025, down from **₹8.65 Lakhs** in 2024. Maximum credit exposure is monitored at **₹0.39 Lakhs**. * **Concentration Risk:** Historically, the company has relied on a single major customer (**Jindal Worldwide Limited**) for over **10%** of its revenue. * **Governance & Compliance:** * **BSE Penalties:** Fines totaling **₹1,08,560** (Regulation 6(1)) and **₹11,800** (Board meeting intimation delay) were recently incurred. * **Board Instability:** Resignation of two Independent Directors in **August 2025** following the Open Offer completion. * **Operational Risks:** * **Commodity Risk:** Exposure to raw material price volatility in the new textile/medical segments, managed via **forward booking**. * **Human Capital:** Risk of talent attrition during the pivot; being addressed via a new **strategic talent management system**. * **Technology Risk:** Obsolescence and cyber security threats inherent in the IT service delivery model.